참고문헌
- Bustreo S, Osella-Abate S, Cassoni P, Donadio M, Airoldi M, Pedani F, Papotti M, Sapino A, Castellano I. Optimal Ki-67 cut-off for luminal breast cancer prognostic evaluation: A large case series study with a long-term follow-up. Breast Cancer Research Treatment. 2016. 157: 363-371. https://doi.org/10.1007/s10549-016-3817-9
- Cheang MC, Chia SK, Voduc D, Gao D, Leung S, Snider J, Watson M, Davies S, Bernard PS, Parker JS, Perou CM, Ellis MJ, Nielsen TO. Ki-67 index, her2 status, and prognosis of patients with luminal B breast cancer. Journal of National Cancer Institute. 2009. 101: 736-750. https://doi.org/10.1093/jnci/djp082
- Chung YR, Jang MH, Park SY, Gong G, Jung WH, Korean Breast Pathology Ki-67 Study G. Interobserver variability of Ki-67 measurement in breast cancer. Journal of Pathology and Translational Medicine. 2016. 50: 129-137. https://doi.org/10.4132/jptm.2015.12.24
- Denkert C, von Minckwitz G. Reply to Ki-67 in breast cancer: A useful prognostic marker! Annals of Oncology. 2014. 25: 542-543.
- Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thurlimann B, Senn HJ, Panel M. Strategies for subtypes--dealing with the diversity of breast cancer: Highlights of the St. Gallen international expert consensus on the primary therapy of early breast cancer 2011. Annals of Oncology. 2011. 22: 1736-1747. https://doi.org/10.1093/annonc/mdr304
- Kim TJ, Kim SC. Analysis of the bcl-2, Ki-67 and p53 expression level based on the Gleason score group of prostate adenocarcinoma. Biomedical Science Letter. 2008. 14: 156-165.
- Kim Y, Seok JY, Hyun KY, Lee GH, Choi SC. Correlation of Glasgow pronostic score or procalcitonin to clinical variables in patients with pretreatment lung cancer. Biomedical Science Letter. 2016. 22: 9-17. https://doi.org/10.15616/BSL.2016.22.1.9
- Leong AS, Zhuang Z. The changing role of pathology in breast cancer diagnosis and treatment. Pathobiology. 2011. 78: 99-114. https://doi.org/10.1159/000292644
- Luporsi E, Andre F, Spyratos F, Martin PM, Jacquemier J, Penault-Llorca F, Tubiana-Mathieu N, Sigal-Zafrani B, Arnould L, Gompel A, Egele C, Poulet B, Clough KB, Crouet H, Fourquet A, Lefranc JP, Mathelin C, Rouyer N, Serin D, Spielmann M, Haugh M, Chenard MP, Brain E, Cremoux P, Bellocq JP. Ki-67: Level of evidence and methodological considerations for its role in the clinical management of breast cancer: Analytical and critical review. Breast Cancer Research Treatment. 2012. 132: 895-915. https://doi.org/10.1007/s10549-011-1837-z
- Moerland E, Van Hezik RL, Van Der Aa TC, Van Beek MW, Van Den Brule AJ. Detection of her2 amplification in breast carcinomas: Comparison of multiplex ligation-dependent probe amplification (MLPA) and fluorescence in situ hybridization (FISH) combined with automated spot counting. Cellular Oncology. 2006. 28: 151-159.
- O'Brien KM, Cole SR, Tse CK, Perou CM, Carey LA, Foulkes WD, Dressler LG, Geradts J, Millikan RC. Intrinsic breast tumor subtypes, race, and long-term survival in the carolina breast cancer study. Clinical Cancer Research. 2010. 16: 6100-6110. https://doi.org/10.1158/1078-0432.CCR-10-1533
- Shokouh TZ, Ezatollah A, Barand P. Interrelationships between Ki-67, her2/neu, p53, er, and pr status and their associations with tumor grade and lymph node involvement in breast carcinoma subtypes retrospective-observational analytical study. Medicine. 2015. 94: e1359. https://doi.org/10.1097/MD.0000000000001359
- Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA: A Cancer Journal for Clinicians. 2016. 66: 7-30. https://doi.org/10.3322/caac.21332
- Tan QX, Qin QH, Yang WP, Mo QG, Wei CY. Prognostic value of Ki-67 expression in HR-negative breast cancer before and after neoadjuvant chemotherapy. International Journal of Clinical and Experimental Pathology. 2014. 7: 6862-6870.
- Tashima R, Nishimura R, Osako T, Nishiyama Y, Okumura Y, Nakano M, Fujisue M, Toyozumi Y, Arima N. Evaluation of an optimal cut-off point for the Ki-67 index as a prognostic factor in primary breast cancer: A retrospective study. PLOS One. 2015. 10: e0119565. https://doi.org/10.1371/journal.pone.0119565
- Trihia H, Murray S, Price K, Gelber RD, Golouh R, Goldhirsch A, Coates AS, Collins J, Castiglione-Gertsch M, Gusterson BA, International Breast Cancer Study G. Ki-67 expression in breast carcinoma: Its association with grading systems, clinical parameters, and other prognostic factors-a surrogate marker? Cancer. 2003. 97: 1321-1331. https://doi.org/10.1002/cncr.11188
- Yan J, Liu XL, Han LZ, Xiao G, Li NL, Deng YN, Yin LC, Ling LJ, Yu XY, Tan CL, Huang XP, Liu LX. Relation between Ki-67, ER, PR, HER2/Neu, p21, EGFR, and Top II-alpha expression in invasive ductal breast cancer patients and correlations with prognosis. Asian Pacific Journal of Cancer Prevention. 2015. 16: 823-829. https://doi.org/10.7314/APJCP.2015.16.2.823